LIPID-LOWERING THERAPY IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE

One of the major risk factors for cardiovascular disease (CVD) and atherosclerosis is dyslipidemia. The liver plays an important role in the development of disorders of lipid metabolism; so, treatment of CVD involves the application of hepatoprotectors that reasonable from the viewpoint of the pathogenesis of disease. The article presents an algorithm for correction of dyslipidemia and nonalcoholic fatty liver disease.

lipid metabolism, atherosclerosis, dyslipidemia, non-alcoholic fatty liver disease, hypolipidemic therapy, statins, essential phospholipids, ademetionine